[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$flqyOfVr1zxVUF0hHPjXm1ynPJ-Vfr71IgEl8rTyTc-M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":83,"rows":90},"China Medical University Hospital",[4],458,false,82,13,819277,26,348,[14,17,19,22,25,28,31,33],{"name":15,"count":16},"Schizophrenia",11,{"name":18,"count":16},"Stroke",{"name":20,"count":21},"Breast Cancer",9,{"name":23,"count":24},"Acupuncture",8,{"name":26,"count":27},"Knee Osteoarthritis",7,{"name":29,"count":30},"Major Depressive Disorder",6,{"name":32,"count":30},"Ischemic Stroke",{"name":34,"count":30},"Healthy",[36,41,46,51,56,61,66,71,76,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05482451","Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer","2025-02-28","Nivolumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07235488","Effectiveness of Integrative Medical Treatment in Sudden Hearing Loss","2026-05-20","steroid therapy",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07363551","Omega-3 Fatty Acids, Inflammation, Gut Microbiota in Youth With Depression","2026-05-31","Omega-3 fatty acids",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07003139","A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors","2026-06","B10 L-BPA",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06071013","Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","2026-08-27","Nintedanib, gefitinib, erlotinib, afatinib, osimertinib",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06952868","Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers","2026-08-31","Drug: B10 L-BPA",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05052853","Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer","2026-10","NMDAE",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06598917","Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT","2026-10-30","S-1",{"nctId":77,"briefTitle":78,"date":79,"intervention":70},"NCT04637620","NMDA Modulation in Major Depressive Disorder","2026-11",{"nctId":81,"briefTitle":82,"date":79,"intervention":70},"NCT05136755","NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,121,192,234,257,295,318,336,356,379,404,422,443,461,488,513,531,564,588,606,630,648,673,691,711,738,760,808,842,860,887,905,932,956,980,1005,1023,1051,1069,1087,1113,1141,1167,1185,1223,1246,1273,1297,1323,1341,1365,1392,1410,1435,1457,1496,1527,1552,1576,1598,1621,1647,1665,1683,1709,1727,1751,1773,1797,1822,1846,1871,1889,1913,1936,1960,1978,2000,2025,2043,2065,2089,2114,2136,2163,2181,2206,2228,2251,2279,2297,2324,2342,2368,2395,2413,2431,2457,2484,2509,2530,2557,2582,2600,2624,2648,2674,2698,2723,2748,2771,2797,2822,2851,2869,2887,2916,2934,2958,2983,3006,3035,3060,3085,3112,3137],{"intervention":92,"totalTrials":93,"cells":94},"Dexamethasone and N-acetylcysteine",1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":119},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":111},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":118},"NCT06811675","The Efficacy of Dexamethasone in Combination With N-acetylcysteine in Preventing Neurocognitive Sequelae Due to Carbon Monoxide Poisoning","RECRUITING",[88],"2027-06-30","2027-09-30","2025-03-23",128,[116,117],"Carbon Monoxide Poisoning","Delayed Neurocognitive Sequelae",[92],{"trials":120,"activeCount":97},[],{"intervention":70,"totalTrials":27,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":186,"PHASE4":188,"NA":190},{"trials":124,"activeCount":97},[],{"trials":126,"activeCount":97},[],{"trials":128,"activeCount":27,"soonestReadout":69},[129,139,147,156,164,173,179],{"nctId":130,"briefTitle":131,"status":109,"phases":132,"primaryCompletion":133,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},"NCT04745143","Monotherapy of an NMDA Enhancer for Schizophrenia",[86],"2027-09","2027-12","2018-01-01",80,[15],[70],{"nctId":77,"briefTitle":78,"status":109,"phases":140,"primaryCompletion":79,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":145},[86],"2026-12","2017-06-01",90,[29],[70,146],"Sertraline",{"nctId":148,"briefTitle":149,"status":109,"phases":150,"primaryCompletion":151,"completion":134,"start":152,"enrollment":143,"conditions":153,"interventions":155},"NCT05977023","NMDA Receptor Modulation for the Treatment of Bipolar I Disorder",[86],"2027-11","2023-10-04",[154],"Bipolar I Disorder",[70],{"nctId":157,"briefTitle":158,"status":109,"phases":159,"primaryCompletion":134,"completion":160,"start":161,"enrollment":143,"conditions":162,"interventions":163},"NCT06021197","NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia",[86],"2028-03","2023-10-12",[15],[70],{"nctId":165,"briefTitle":166,"status":109,"phases":167,"primaryCompletion":168,"completion":169,"start":170,"enrollment":143,"conditions":171,"interventions":172},"NCT07122895","Sex Differences in NMDA-enhancing Treatment of Schizophrenia",[86],"2029-12","2030-03","2025-09-16",[15],[70],{"nctId":81,"briefTitle":82,"status":109,"phases":174,"primaryCompletion":79,"completion":141,"start":175,"enrollment":176,"conditions":177,"interventions":178},[86],"2022-01-25",50,[29],[70],{"nctId":67,"briefTitle":68,"status":109,"phases":180,"primaryCompletion":69,"completion":141,"start":181,"enrollment":182,"conditions":183,"interventions":185},[86],"2021-11-01",48,[184],"Prodromal Schizophrenia",[70],{"trials":187,"activeCount":97},[],{"trials":189,"activeCount":97},[],{"trials":191,"activeCount":97},[],{"intervention":193,"totalTrials":194,"cells":195},"NMDAE plus Placebo Cap",3,{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":197,"activeCount":97},[],{"trials":199,"activeCount":97},[],{"trials":201,"activeCount":194,"soonestReadout":79},[202,212,220],{"nctId":203,"briefTitle":204,"status":109,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":136,"conditions":209,"interventions":210},"NCT05240976","Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia",[86],"2027-02","2027-03","2022-02-23",[15],[211,193],"NMDAE plus AIFA",{"nctId":213,"briefTitle":214,"status":109,"phases":215,"primaryCompletion":141,"completion":207,"start":216,"enrollment":143,"conditions":217,"interventions":218},"NCT04959201","Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia",[86],"2020-11-30",[15],[219,193],"NMDAE plus AO",{"nctId":221,"briefTitle":222,"status":109,"phases":223,"primaryCompletion":79,"completion":141,"start":224,"enrollment":225,"conditions":226,"interventions":227},"NCT04917302","Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia",[86],"2020-10-13",60,[15],[211,193],{"trials":229,"activeCount":97},[],{"trials":231,"activeCount":97},[],{"trials":233,"activeCount":97},[],{"intervention":211,"totalTrials":235,"cells":236},2,{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":238,"activeCount":97},[],{"trials":240,"activeCount":97},[],{"trials":242,"activeCount":235,"soonestReadout":79},[243,247],{"nctId":203,"briefTitle":204,"status":109,"phases":244,"primaryCompletion":206,"completion":207,"start":208,"enrollment":136,"conditions":245,"interventions":246},[86],[15],[211,193],{"nctId":221,"briefTitle":222,"status":109,"phases":248,"primaryCompletion":79,"completion":141,"start":224,"enrollment":225,"conditions":249,"interventions":250},[86],[15],[211,193],{"trials":252,"activeCount":97},[],{"trials":254,"activeCount":97},[],{"trials":256,"activeCount":97},[],{"intervention":258,"totalTrials":235,"cells":259},"Alectinib",{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":275,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":261,"activeCount":97},[],{"trials":263,"activeCount":97},[264],{"nctId":265,"briefTitle":266,"status":267,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT06354387","Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1","COMPLETED",[85],"2026-02-28","2022-02-16",5,[273],"Hepatocellular Carcinoma",[258],{"trials":276,"activeCount":93,"soonestReadout":282},[277],{"nctId":278,"briefTitle":279,"status":280,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT07560410","Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)","NOT_YET_RECRUITING",[85,86],"2029-01-15","2029-04-14","2026-05-15",10,[287],"Bone Cancer",[258],{"trials":290,"activeCount":97},[],{"trials":292,"activeCount":97},[],{"trials":294,"activeCount":97},[],{"intervention":65,"totalTrials":93,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":312,"PHASE4":314,"NA":316},{"trials":298,"activeCount":97},[],{"trials":300,"activeCount":97},[],{"trials":302,"activeCount":93,"soonestReadout":64},[303],{"nctId":62,"briefTitle":63,"status":109,"phases":304,"primaryCompletion":64,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":311},[86],"2027-02-28","2025-05-23",24,[309,310],"Head and Neck Cancer","Boron Neutron Capture Therapy",[65],{"trials":313,"activeCount":97},[],{"trials":315,"activeCount":97},[],{"trials":317,"activeCount":97},[],{"intervention":146,"totalTrials":93,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":321,"activeCount":97},[],{"trials":323,"activeCount":97},[],{"trials":325,"activeCount":93,"soonestReadout":79},[326],{"nctId":77,"briefTitle":78,"status":109,"phases":327,"primaryCompletion":79,"completion":141,"start":142,"enrollment":143,"conditions":328,"interventions":329},[86],[29],[70,146],{"trials":331,"activeCount":97},[],{"trials":333,"activeCount":97},[],{"trials":335,"activeCount":97},[],{"intervention":55,"totalTrials":93,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":339,"activeCount":97},[],{"trials":341,"activeCount":97},[],{"trials":343,"activeCount":93,"soonestReadout":54},[344],{"nctId":52,"briefTitle":53,"status":109,"phases":345,"primaryCompletion":54,"completion":141,"start":346,"enrollment":285,"conditions":347,"interventions":349},[85,86],"2025-06-30",[348],"Malignant Brain Tumors",[55],{"trials":351,"activeCount":97},[],{"trials":353,"activeCount":97},[],{"trials":355,"activeCount":97},[],{"intervention":60,"totalTrials":93,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":359,"activeCount":97},[],{"trials":361,"activeCount":97},[],{"trials":363,"activeCount":93,"soonestReadout":59},[364],{"nctId":57,"briefTitle":58,"status":109,"phases":365,"primaryCompletion":59,"completion":59,"start":366,"enrollment":367,"conditions":368,"interventions":372},[85,86],"2024-02-23",20,[369,370,371],"Non-small Cell Lung Cancer","EGFR Gene Mutation","EGFR-TKI Resistant Mutation",[60],{"trials":374,"activeCount":97},[],{"trials":376,"activeCount":97},[],{"trials":378,"activeCount":97},[],{"intervention":380,"totalTrials":93,"cells":381},"S1RA plus NMDAE",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":398,"PHASE4":400,"NA":402},{"trials":383,"activeCount":97},[],{"trials":385,"activeCount":97},[],{"trials":387,"activeCount":93,"soonestReadout":392},[388],{"nctId":389,"briefTitle":390,"status":109,"phases":391,"primaryCompletion":392,"completion":393,"start":394,"enrollment":143,"conditions":395,"interventions":396},"NCT06574360","Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia",[86],"2028-12","2029-03","2024-09-23",[15],[380,397],"S1RA plus Placebo Cap",{"trials":399,"activeCount":97},[],{"trials":401,"activeCount":97},[],{"trials":403,"activeCount":97},[],{"intervention":397,"totalTrials":93,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":407,"activeCount":97},[],{"trials":409,"activeCount":97},[],{"trials":411,"activeCount":93,"soonestReadout":392},[412],{"nctId":389,"briefTitle":390,"status":109,"phases":413,"primaryCompletion":392,"completion":393,"start":394,"enrollment":143,"conditions":414,"interventions":415},[86],[15],[380,397],{"trials":417,"activeCount":97},[],{"trials":419,"activeCount":97},[],{"trials":421,"activeCount":97},[],{"intervention":75,"totalTrials":93,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":425,"activeCount":97},[],{"trials":427,"activeCount":97},[],{"trials":429,"activeCount":93,"soonestReadout":74},[430],{"nctId":72,"briefTitle":73,"status":280,"phases":431,"primaryCompletion":74,"completion":432,"start":433,"enrollment":225,"conditions":434,"interventions":436},[86],"2028-10-30","2024-10-01",[435],"Locally Advanced Unresectable Esophageal Cancer",[75],{"trials":438,"activeCount":97},[],{"trials":440,"activeCount":97},[],{"trials":442,"activeCount":97},[],{"intervention":219,"totalTrials":93,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":455,"PHASE4":457,"NA":459},{"trials":446,"activeCount":97},[],{"trials":448,"activeCount":97},[],{"trials":450,"activeCount":93,"soonestReadout":141},[451],{"nctId":213,"briefTitle":214,"status":109,"phases":452,"primaryCompletion":141,"completion":207,"start":216,"enrollment":143,"conditions":453,"interventions":454},[86],[15],[219,193],{"trials":456,"activeCount":97},[],{"trials":458,"activeCount":97},[],{"trials":460,"activeCount":97},[],{"intervention":462,"totalTrials":93,"cells":463},"ADSC01",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":465,"activeCount":97},[],{"trials":467,"activeCount":97},[],{"trials":469,"activeCount":93,"soonestReadout":474},[470],{"nctId":471,"briefTitle":472,"status":109,"phases":473,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":481},"NCT06574581","ADSCs Therapy in Patients With CTD-ILD",[85,86],"2027-04-30","2027-11-30","2024-08-20",16,[479,480],"Connective Tissue Diseases","Interstitial Lung Disease",[462],{"trials":483,"activeCount":97},[],{"trials":485,"activeCount":97},[],{"trials":487,"activeCount":97},[],{"intervention":489,"totalTrials":93,"cells":490},"Imatinib",{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":492,"activeCount":97},[],{"trials":494,"activeCount":93,"soonestReadout":499},[495],{"nctId":496,"briefTitle":497,"status":109,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":285,"conditions":501,"interventions":503},"NCT06962254","Imatinib and Trametinib for KRAS-mutated Solid Tumor",[85],"2028-03-31","2025-05-10",[502],"Solid Tumor Cancer",[489,504],"Trametinib",{"trials":506,"activeCount":97},[],{"trials":508,"activeCount":97},[],{"trials":510,"activeCount":97},[],{"trials":512,"activeCount":97},[],{"intervention":504,"totalTrials":93,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":523,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":516,"activeCount":97},[],{"trials":518,"activeCount":93,"soonestReadout":499},[519],{"nctId":496,"briefTitle":497,"status":109,"phases":520,"primaryCompletion":499,"completion":499,"start":500,"enrollment":285,"conditions":521,"interventions":522},[85],[502],[489,504],{"trials":524,"activeCount":97},[],{"trials":526,"activeCount":97},[],{"trials":528,"activeCount":97},[],{"trials":530,"activeCount":97},[],{"intervention":40,"totalTrials":235,"cells":532},{"EARLY_PHASE1":533,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":549,"NA":551},{"trials":534,"activeCount":93,"soonestReadout":39},[535],{"nctId":37,"briefTitle":38,"status":536,"phases":537,"primaryCompletion":39,"completion":39,"start":538,"enrollment":285,"conditions":539,"interventions":541},"ACTIVE_NOT_RECRUITING",[84],"2021-03-01",[540],"Effect of Drug",[40,542],"all trans retinoic acid",{"trials":544,"activeCount":97},[],{"trials":546,"activeCount":97},[],{"trials":548,"activeCount":97},[],{"trials":550,"activeCount":97},[],{"trials":552,"activeCount":93,"soonestReadout":141},[553],{"nctId":554,"briefTitle":555,"status":556,"phases":557,"primaryCompletion":141,"completion":141,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT05745233","Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites","ENROLLING_BY_INVITATION",[89],"2021-01-01",30,[561],"Malignant Ascites",[40,563],"Pembrolizumab",{"intervention":565,"totalTrials":93,"cells":566},"Methylene Blue",{"EARLY_PHASE1":567,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":568,"activeCount":93,"soonestReadout":573},[569],{"nctId":570,"briefTitle":571,"status":536,"phases":572,"primaryCompletion":573,"completion":111,"start":574,"enrollment":285,"conditions":575,"interventions":577},"NCT07435415","Local Injection Methylene Blue Combined With Radiation in HNSCC Patients",[84],"2026-12-31","2025-08-01",[309,576],"Local Recurrent Tumor",[565],{"trials":579,"activeCount":97},[],{"trials":581,"activeCount":97},[],{"trials":583,"activeCount":97},[],{"trials":585,"activeCount":97},[],{"trials":587,"activeCount":97},[],{"intervention":542,"totalTrials":93,"cells":589},{"EARLY_PHASE1":590,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":591,"activeCount":93,"soonestReadout":39},[592],{"nctId":37,"briefTitle":38,"status":536,"phases":593,"primaryCompletion":39,"completion":39,"start":538,"enrollment":285,"conditions":594,"interventions":595},[84],[540],[40,542],{"trials":597,"activeCount":97},[],{"trials":599,"activeCount":97},[],{"trials":601,"activeCount":97},[],{"trials":603,"activeCount":97},[],{"trials":605,"activeCount":97},[],{"intervention":607,"totalTrials":93,"cells":608},"Traditional Chinese Medicine treatment",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":617,"NA":619},{"trials":610,"activeCount":97},[],{"trials":612,"activeCount":97},[],{"trials":614,"activeCount":97},[],{"trials":616,"activeCount":97},[],{"trials":618,"activeCount":97},[],{"trials":620,"activeCount":93,"soonestReadout":573},[621],{"nctId":622,"briefTitle":623,"status":109,"phases":624,"primaryCompletion":573,"completion":625,"start":626,"enrollment":367,"conditions":627,"interventions":629},"NCT07136935","A Multicenter Observational Study of an Integrated Traditional Chinese and Western Medicine Care Model in Post-Acute Treatment of Frail Elderly Patients",[89],"2027-03-31","2025-07-28",[628],"Frail Elderly Patients",[607],{"intervention":563,"totalTrials":93,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":640,"NA":642},{"trials":633,"activeCount":97},[],{"trials":635,"activeCount":97},[],{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":97},[],{"trials":641,"activeCount":97},[],{"trials":643,"activeCount":93,"soonestReadout":141},[644],{"nctId":554,"briefTitle":555,"status":556,"phases":645,"primaryCompletion":141,"completion":141,"start":558,"enrollment":559,"conditions":646,"interventions":647},[89],[561],[40,563],{"intervention":649,"totalTrials":93,"cells":650},"0.01% concentration atropine drops",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":652,"activeCount":97},[],{"trials":654,"activeCount":97},[],{"trials":656,"activeCount":97},[],{"trials":658,"activeCount":97},[],{"trials":660,"activeCount":97},[],{"trials":662,"activeCount":93,"soonestReadout":573},[663],{"nctId":664,"briefTitle":665,"status":556,"phases":666,"primaryCompletion":573,"completion":625,"start":667,"enrollment":668,"conditions":669,"interventions":671},"NCT07537166","0.01% and 0.025% Atropine Eye Drops Combined Auricular Acupoint Stimulation on Myopia Control and Corneal Endothelium Change",[89],"2026-02-27",420,[670],"Acupressure",[649,672],"0.025% atropine eye drops",{"intervention":672,"totalTrials":93,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":676,"activeCount":97},[],{"trials":678,"activeCount":97},[],{"trials":680,"activeCount":97},[],{"trials":682,"activeCount":97},[],{"trials":684,"activeCount":97},[],{"trials":686,"activeCount":93,"soonestReadout":573},[687],{"nctId":664,"briefTitle":665,"status":556,"phases":688,"primaryCompletion":573,"completion":625,"start":667,"enrollment":668,"conditions":689,"interventions":690},[89],[670],[649,672],{"intervention":50,"totalTrials":93,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":694,"activeCount":97},[],{"trials":696,"activeCount":97},[],{"trials":698,"activeCount":97},[],{"trials":700,"activeCount":97},[],{"trials":702,"activeCount":97},[],{"trials":704,"activeCount":93,"soonestReadout":49},[705],{"nctId":47,"briefTitle":48,"status":109,"phases":706,"primaryCompletion":49,"completion":49,"start":707,"enrollment":225,"conditions":708,"interventions":710},[89],"2021-06-09",[709],"ADHD",[50],{"intervention":712,"totalTrials":93,"cells":713},"Blood Biomarker Sampling",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":724},{"trials":715,"activeCount":97},[],{"trials":717,"activeCount":97},[],{"trials":719,"activeCount":97},[],{"trials":721,"activeCount":97},[],{"trials":723,"activeCount":97},[],{"trials":725,"activeCount":93,"soonestReadout":730},[726],{"nctId":727,"briefTitle":728,"status":109,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":737},"NCT07232667","Digital Technology for Active and Healthy Ageing in Taiwan",[],"2028-12-31","2029-12-31","2026-04-22",140,[735,736],"Healthy Aging","Digital Health Literacy",[712],{"intervention":45,"totalTrials":93,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":741,"activeCount":97},[],{"trials":743,"activeCount":97},[],{"trials":745,"activeCount":97},[],{"trials":747,"activeCount":97},[],{"trials":749,"activeCount":97},[],{"trials":751,"activeCount":93,"soonestReadout":44},[752],{"nctId":42,"briefTitle":43,"status":109,"phases":753,"primaryCompletion":44,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},[89],"2026-06-20","2024-07-08",64,[758],"Sudden Hearing Loss",[45],{"intervention":761,"totalTrials":194,"cells":762},"Misoprostol",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":776,"PHASE3":778,"PHASE4":791,"NA":806},{"trials":764,"activeCount":97},[],{"trials":766,"activeCount":97},[767],{"nctId":768,"briefTitle":769,"status":267,"phases":770,"primaryCompletion":771,"completion":771,"start":772,"enrollment":285,"conditions":773,"interventions":775},"NCT01271257","Pharmacokinetics of Misoprostol With Titrated Oral Administration",[85],"2014-12","2011-01",[774],"Hypotonic; Labor",[761],{"trials":777,"activeCount":97},[],{"trials":779,"activeCount":97},[780],{"nctId":781,"briefTitle":782,"status":267,"phases":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":789},"NCT00529295","Titrated Oral Compared With Vaginal Misoprostol for Labor Induction at Term",[87],"2007-03","2005-06",220,[788],"Labor Induction",[790],"misoprostol",{"trials":792,"activeCount":97},[793],{"nctId":794,"briefTitle":795,"status":796,"phases":797,"primaryCompletion":798,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":804},"NCT00695331","Efficacy and Safety Study of Titrated Oral Misoprostol Solution for Labor Augmentation","UNKNOWN",[88],"2008-12","2009-01","2008-02",143,[803],"Labor",[761,805],"Oxytocin",{"trials":807,"activeCount":97},[],{"intervention":809,"totalTrials":235,"cells":810},"Chinese Herb Astragalus membranaceus",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":827,"PHASE4":829,"NA":840},{"trials":812,"activeCount":97},[],{"trials":814,"activeCount":97},[],{"trials":816,"activeCount":97},[817],{"nctId":818,"briefTitle":819,"status":267,"phases":820,"primaryCompletion":821,"completion":822,"start":823,"enrollment":136,"conditions":824,"interventions":826},"NCT01428401","Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke",[86],"2010-12","2011-03","2008-01",[18,825],"Hemorrhagic Transformation Due to Acute Stroke",[809],{"trials":828,"activeCount":97},[],{"trials":830,"activeCount":97},[831],{"nctId":832,"briefTitle":833,"status":796,"phases":834,"primaryCompletion":835,"start":836,"enrollment":143,"conditions":837,"interventions":839},"NCT01554787","Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue",[88],"2013-12","2012-01",[838,18],"Fatigue",[809],{"trials":841,"activeCount":97},[],{"intervention":805,"totalTrials":93,"cells":843},{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":850,"PHASE4":852,"NA":858},{"trials":845,"activeCount":97},[],{"trials":847,"activeCount":97},[],{"trials":849,"activeCount":97},[],{"trials":851,"activeCount":97},[],{"trials":853,"activeCount":97},[854],{"nctId":794,"briefTitle":795,"status":796,"phases":855,"primaryCompletion":798,"completion":799,"start":800,"enrollment":801,"conditions":856,"interventions":857},[88],[803],[761,805],{"trials":859,"activeCount":97},[],{"intervention":861,"totalTrials":93,"cells":862},"Naldebain",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":885},{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[],{"trials":868,"activeCount":97},[],{"trials":870,"activeCount":97},[],{"trials":872,"activeCount":97},[873],{"nctId":874,"briefTitle":875,"status":796,"phases":876,"primaryCompletion":877,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":883},"NCT03854851","NALDEBAIN for Postoperative Pain Management in Take Down of Anastomosis",[88],"2019-07-31","2019-10-31","2019-03-01",40,[882],"Postoperative Pain",[861,884],"Morpine",{"trials":886,"activeCount":97},[],{"intervention":884,"totalTrials":93,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":903},{"trials":890,"activeCount":97},[],{"trials":892,"activeCount":97},[],{"trials":894,"activeCount":97},[],{"trials":896,"activeCount":97},[],{"trials":898,"activeCount":97},[899],{"nctId":874,"briefTitle":875,"status":796,"phases":900,"primaryCompletion":877,"completion":878,"start":879,"enrollment":880,"conditions":901,"interventions":902},[88],[882],[861,884],{"trials":904,"activeCount":97},[],{"intervention":906,"totalTrials":93,"cells":907},"MIYAIRI 588",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":930},{"trials":909,"activeCount":97},[],{"trials":911,"activeCount":97},[],{"trials":913,"activeCount":97},[],{"trials":915,"activeCount":97},[],{"trials":917,"activeCount":97},[918],{"nctId":919,"briefTitle":920,"status":267,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":929},"NCT05724511","The Effect of Probiotics on Depression Syndrome and Risk Factors of Cardiovascular Disease in Hemodialysis Patients",[88],"2023-06-30","2023-07-31","2023-02-27",55,[927,928],"Depression Mild","Cardiovascular Diseases",[906],{"trials":931,"activeCount":97},[],{"intervention":933,"totalTrials":93,"cells":934},"Chinese Herb Huang-Chi-Wu-Wu-Tang",{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":954},{"trials":936,"activeCount":97},[],{"trials":938,"activeCount":97},[],{"trials":940,"activeCount":97},[],{"trials":942,"activeCount":97},[],{"trials":944,"activeCount":97},[945],{"nctId":946,"briefTitle":947,"status":796,"phases":948,"primaryCompletion":949,"start":950,"enrollment":136,"conditions":951,"interventions":953},"NCT01553643","A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis",[88],"2012-11","2010-01",[952],"Intracranial Arterial Stenosis",[933],{"trials":955,"activeCount":97},[],{"intervention":957,"totalTrials":93,"cells":958},"Cilostazol",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":978},{"trials":960,"activeCount":97},[],{"trials":962,"activeCount":97},[],{"trials":964,"activeCount":97},[],{"trials":966,"activeCount":97},[],{"trials":968,"activeCount":97},[969],{"nctId":970,"briefTitle":971,"status":267,"phases":972,"primaryCompletion":973,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":977},"NCT01188824","The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)",[88],"2013-07","2010-09",801,[32],[957],{"trials":979,"activeCount":97},[],{"intervention":981,"totalTrials":93,"cells":982},"Xiang Sha Liu Jun Zi Decoction dry powder",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":991,"NA":1003},{"trials":984,"activeCount":97},[],{"trials":986,"activeCount":97},[],{"trials":988,"activeCount":97},[],{"trials":990,"activeCount":97},[],{"trials":992,"activeCount":97},[993],{"nctId":994,"briefTitle":995,"status":267,"phases":996,"primaryCompletion":997,"completion":998,"start":999,"enrollment":285,"conditions":1000,"interventions":1001},"NCT04562428","The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial",[88],"2020-12-31","2023-05-30","2020-11-20",[273],[981,1002],"XSLJZ Placebo",{"trials":1004,"activeCount":97},[],{"intervention":1002,"totalTrials":93,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1021},{"trials":1008,"activeCount":97},[],{"trials":1010,"activeCount":97},[],{"trials":1012,"activeCount":97},[],{"trials":1014,"activeCount":97},[],{"trials":1016,"activeCount":97},[1017],{"nctId":994,"briefTitle":995,"status":267,"phases":1018,"primaryCompletion":997,"completion":998,"start":999,"enrollment":285,"conditions":1019,"interventions":1020},[88],[273],[981,1002],{"trials":1022,"activeCount":97},[],{"intervention":1024,"totalTrials":93,"cells":1025},"Atomoxetine 80mg combined with oxybutynin 5mg",{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1049},{"trials":1027,"activeCount":97},[],{"trials":1029,"activeCount":97},[],{"trials":1031,"activeCount":97},[],{"trials":1033,"activeCount":97},[],{"trials":1035,"activeCount":97},[1036],{"nctId":1037,"briefTitle":1038,"status":267,"phases":1039,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1046},"NCT06295562","Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea",[88],"2025-10-10","2025-10-22","2024-11-05",45,[1045],"Obstructive Sleep Apnea of Adult",[1024,1047,1048],"Venlafaxine 37.5mg","oxybutynin 5mg combined with trazodone 100mg",{"trials":1050,"activeCount":97},[],{"intervention":1047,"totalTrials":93,"cells":1052},{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1061,"NA":1067},{"trials":1054,"activeCount":97},[],{"trials":1056,"activeCount":97},[],{"trials":1058,"activeCount":97},[],{"trials":1060,"activeCount":97},[],{"trials":1062,"activeCount":97},[1063],{"nctId":1037,"briefTitle":1038,"status":267,"phases":1064,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1065,"interventions":1066},[88],[1045],[1024,1047,1048],{"trials":1068,"activeCount":97},[],{"intervention":1048,"totalTrials":93,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1085},{"trials":1072,"activeCount":97},[],{"trials":1074,"activeCount":97},[],{"trials":1076,"activeCount":97},[],{"trials":1078,"activeCount":97},[],{"trials":1080,"activeCount":97},[1081],{"nctId":1037,"briefTitle":1038,"status":267,"phases":1082,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1083,"interventions":1084},[88],[1045],[1024,1047,1048],{"trials":1086,"activeCount":97},[],{"intervention":1088,"totalTrials":93,"cells":1089},"Wu-Chu-Yu tang",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1096,"PHASE4":1098,"NA":1111},{"trials":1091,"activeCount":97},[],{"trials":1093,"activeCount":97},[],{"trials":1095,"activeCount":97},[],{"trials":1097,"activeCount":97},[],{"trials":1099,"activeCount":97},[1100],{"nctId":1101,"briefTitle":1102,"status":796,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":925,"conditions":1106,"interventions":1110},"NCT04118647","Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder",[88],"2021-09","2019-10",[1107,1108,1109],"Wu-Chu-Yu Tang","Gastroesophageal Reflux Disorder","24 Hours Esophageal PH and Multichannel Intraluminal Impedance Testing",[1088],{"trials":1112,"activeCount":97},[],{"intervention":1114,"totalTrials":93,"cells":1115},"Budesonide-Surfactant",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1139},{"trials":1117,"activeCount":97},[],{"trials":1119,"activeCount":97},[],{"trials":1121,"activeCount":97},[],{"trials":1123,"activeCount":97},[],{"trials":1125,"activeCount":97},[1126],{"nctId":1127,"briefTitle":1128,"status":1129,"phases":1130,"start":1131,"enrollment":559,"conditions":1132,"interventions":1138},"NCT00146497","Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants","TERMINATED",[88],"2004-08",[1133,1134,1135,1136,1137],"Premature Infants","Respiratory Distress Syndrome","Chronic Lung Disease","Bronchoalveolar Lavage Fluid","Cytokines",[1114],{"trials":1140,"activeCount":97},[],{"intervention":1142,"totalTrials":93,"cells":1143},"mirabegron",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1152,"NA":1165},{"trials":1145,"activeCount":97},[],{"trials":1147,"activeCount":97},[],{"trials":1149,"activeCount":97},[],{"trials":1151,"activeCount":97},[],{"trials":1153,"activeCount":97},[1154],{"nctId":1155,"briefTitle":1156,"status":796,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":176,"conditions":1160,"interventions":1163},"NCT04909255","Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder",[88],"2022-08-15","2021-03-23",[1161,1162],"Sjogren's Syndrome","Overactive Bladder Syndrome",[1142,1164],"oxybutynin, tolterodine, solifenacin",{"trials":1166,"activeCount":97},[],{"intervention":1164,"totalTrials":93,"cells":1168},{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1183},{"trials":1170,"activeCount":97},[],{"trials":1172,"activeCount":97},[],{"trials":1174,"activeCount":97},[],{"trials":1176,"activeCount":97},[],{"trials":1178,"activeCount":97},[1179],{"nctId":1155,"briefTitle":1156,"status":796,"phases":1180,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":176,"conditions":1181,"interventions":1182},[88],[1161,1162],[1142,1164],{"trials":1184,"activeCount":97},[],{"intervention":1186,"totalTrials":235,"cells":1187},"TCM Formula",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1207,"PHASE4":1219,"NA":1221},{"trials":1189,"activeCount":97},[],{"trials":1191,"activeCount":97},[],{"trials":1193,"activeCount":97},[1194],{"nctId":1195,"briefTitle":1196,"status":796,"phases":1197,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":225,"conditions":1200,"interventions":1204},"NCT04785261","Effect of Traditional Chinese Medicine on Basic Tear Secretion and Tear Cytokines in Patients With Dry Eye Disease",[86],"2022-05-31","2021-03-16",[1201,1202,1203],"Dry Eye Disease","Dry Eye Syndromes","Dry Eye",[1205,1206,1186],"Methylhydroxypropylcellulose","Carbomer",{"trials":1208,"activeCount":97},[1209],{"nctId":1210,"briefTitle":1211,"status":267,"phases":1212,"primaryCompletion":1213,"completion":1214,"start":1215,"enrollment":559,"conditions":1216,"interventions":1218},"NCT05204758","Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect",[87],"2017-12-31","2021-02-28","2016-05-12",[1217],"Advanced Lung Adenocarcinoma",[1186],{"trials":1220,"activeCount":97},[],{"trials":1222,"activeCount":97},[],{"intervention":1224,"totalTrials":93,"cells":1225},"EWO1",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1242,"NA":1244},{"trials":1227,"activeCount":97},[],{"trials":1229,"activeCount":97},[],{"trials":1231,"activeCount":97},[],{"trials":1233,"activeCount":97},[1234],{"nctId":1235,"briefTitle":1236,"status":796,"phases":1237,"start":1238,"enrollment":225,"conditions":1239,"interventions":1241},"NCT00153595","EWO1 in Persistent Allergic Rhinitis Patients",[86,87],"2004-11",[1240],"Rhinitis, Allergic, Perennial",[1224],{"trials":1243,"activeCount":97},[],{"trials":1245,"activeCount":97},[],{"intervention":1247,"totalTrials":93,"cells":1248},"Formosa 1-Breath Free",{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1255,"PHASE4":1269,"NA":1271},{"trials":1250,"activeCount":97},[],{"trials":1252,"activeCount":97},[],{"trials":1254,"activeCount":97},[],{"trials":1256,"activeCount":97},[1257],{"nctId":1258,"briefTitle":1259,"status":796,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1268},"NCT06175468","Evaluate the Efficacy and Safety of \"Formosa 1-Breath Free (NRICM101) \" in Subjects With the Symptoms of COVID-19 or Influenza-like Disease",[87],"2024-04","2024-08","2023-12-15",170,[1266,1267],"Influenza Viral Infections","COVID-19",[1247],{"trials":1270,"activeCount":97},[],{"trials":1272,"activeCount":97},[],{"intervention":1274,"totalTrials":93,"cells":1275},"Xiang-Sha-Liu-Jun-Zi-Tang",{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1282,"PHASE4":1293,"NA":1295},{"trials":1277,"activeCount":97},[],{"trials":1279,"activeCount":97},[],{"trials":1281,"activeCount":97},[],{"trials":1283,"activeCount":97},[1284],{"nctId":1285,"briefTitle":1286,"status":796,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":136,"conditions":1290,"interventions":1292},"NCT02179580","A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome",[86,87],"2015-12","2014-06",[1291],"Irritable Bowel Syndrome",[1274],{"trials":1294,"activeCount":97},[],{"trials":1296,"activeCount":97},[],{"intervention":1298,"totalTrials":93,"cells":1299},"TGF",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1319,"NA":1321},{"trials":1301,"activeCount":97},[],{"trials":1303,"activeCount":97},[],{"trials":1305,"activeCount":97},[],{"trials":1307,"activeCount":97},[1308],{"nctId":1309,"briefTitle":1310,"status":796,"phases":1311,"primaryCompletion":1312,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1317},"NCT03562429","The Efficacy of TGF for Treating Osteoarthritis of the Knee",[86,87],"2021-12-31","2018-08-01",180,[1316],"Osteoarthritis, Knee",[1298,1318],"TGFP",{"trials":1320,"activeCount":97},[],{"trials":1322,"activeCount":97},[],{"intervention":1318,"totalTrials":93,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1337,"NA":1339},{"trials":1326,"activeCount":97},[],{"trials":1328,"activeCount":97},[],{"trials":1330,"activeCount":97},[],{"trials":1332,"activeCount":97},[1333],{"nctId":1309,"briefTitle":1310,"status":796,"phases":1334,"primaryCompletion":1312,"completion":1312,"start":1313,"enrollment":1314,"conditions":1335,"interventions":1336},[86,87],[1316],[1298,1318],{"trials":1338,"activeCount":97},[],{"trials":1340,"activeCount":97},[],{"intervention":1342,"totalTrials":93,"cells":1343},"Trichosanthes root",{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1350,"PHASE4":1361,"NA":1363},{"trials":1345,"activeCount":97},[],{"trials":1347,"activeCount":97},[],{"trials":1349,"activeCount":97},[],{"trials":1351,"activeCount":97},[1352],{"nctId":1353,"briefTitle":1354,"status":796,"phases":1355,"primaryCompletion":1356,"start":1357,"enrollment":225,"conditions":1358,"interventions":1360},"NCT02855645","The Effects of Trichosanthes Root on Blood Sugar in Patients With Diabetes Mellitus",[86,87],"2017-04","2016-07",[1359],"Diabetes Mellitus",[1342],{"trials":1362,"activeCount":97},[],{"trials":1364,"activeCount":97},[],{"intervention":1366,"totalTrials":93,"cells":1367},"5% cysteamine cream",{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1388,"NA":1390},{"trials":1369,"activeCount":97},[],{"trials":1371,"activeCount":97},[],{"trials":1373,"activeCount":97},[],{"trials":1375,"activeCount":97},[1376],{"nctId":1377,"briefTitle":1378,"status":267,"phases":1379,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":1384,"interventions":1386},"NCT05969587","Cysteamine Compared to Hydroquinone in Melasma",[87],"2020-09-11","2020-11-11","2019-11-28",28,[1385],"Melasma",[1366,1387],"hydroquinone cream group",{"trials":1389,"activeCount":97},[],{"trials":1391,"activeCount":97},[],{"intervention":1387,"totalTrials":93,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1406,"NA":1408},{"trials":1395,"activeCount":97},[],{"trials":1397,"activeCount":97},[],{"trials":1399,"activeCount":97},[],{"trials":1401,"activeCount":97},[1402],{"nctId":1377,"briefTitle":1378,"status":267,"phases":1403,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":1404,"interventions":1405},[87],[1385],[1366,1387],{"trials":1407,"activeCount":97},[],{"trials":1409,"activeCount":97},[],{"intervention":1411,"totalTrials":93,"cells":1412},"Astragalus Membranaceus",{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1431,"NA":1433},{"trials":1414,"activeCount":97},[],{"trials":1416,"activeCount":97},[],{"trials":1418,"activeCount":97},[],{"trials":1420,"activeCount":97},[1421],{"nctId":1422,"briefTitle":1423,"status":796,"phases":1424,"primaryCompletion":1425,"completion":1425,"start":1426,"enrollment":1427,"conditions":1428,"interventions":1430},"NCT03271697","Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage",[86,87],"2020-09","2017-09",120,[1429],"Aneurysmal Subarachnoid Hemorrhage",[1411],{"trials":1432,"activeCount":97},[],{"trials":1434,"activeCount":97},[],{"intervention":1436,"totalTrials":93,"cells":1437},"Lipid-lowing Tea",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1444,"PHASE4":1453,"NA":1455},{"trials":1439,"activeCount":97},[],{"trials":1441,"activeCount":97},[],{"trials":1443,"activeCount":97},[],{"trials":1445,"activeCount":97},[1446],{"nctId":1447,"briefTitle":1448,"status":796,"phases":1449,"conditions":1450,"interventions":1452},"NCT00316641","The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients' Lipid Profiles",[87],[1451],"Hyperlipidemia",[1436],{"trials":1454,"activeCount":97},[],{"trials":1456,"activeCount":97},[],{"intervention":1458,"totalTrials":235,"cells":1459},"Sarcosine",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1461,"activeCount":97},[],{"trials":1463,"activeCount":97},[],{"trials":1465,"activeCount":97},[1466,1478],{"nctId":1467,"briefTitle":1468,"status":267,"phases":1469,"completion":1470,"start":1471,"enrollment":367,"conditions":1472,"interventions":1477},"NCT00328276","Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia",[86],"2005-12","2004-12",[1473,1474,1475,1476],"Schizophrenias","Psychoses","Psychotic Disorders","Schizophrenic Disorders",[1458],{"nctId":1479,"briefTitle":1480,"status":267,"phases":1481,"primaryCompletion":1482,"completion":1482,"start":1483,"enrollment":880,"conditions":1484,"interventions":1487},"NCT00977353","N-methylglycine (Sarcosine) Treatment for Depression",[86],"2011-07","2009-04",[29,1485,1486],"Depression","Major Depression",[1488,1489],"citalopram","sarcosine",{"trials":1491,"activeCount":97},[],{"trials":1493,"activeCount":97},[],{"trials":1495,"activeCount":97},[],{"intervention":1497,"totalTrials":235,"cells":1498},"Marine active",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1510,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1500,"activeCount":97},[],{"trials":1502,"activeCount":97},[1503],{"nctId":1504,"briefTitle":1505,"status":796,"phases":1506,"conditions":1507,"interventions":1509},"NCT00207974","Pharmacokinetic Study of Marine Active in Health Men",[85],[1508],"Hyperuricemia, Anserine, Pharmacokinetic",[1497],{"trials":1511,"activeCount":97},[1512],{"nctId":1513,"briefTitle":1514,"status":796,"phases":1515,"completion":1516,"start":1517,"conditions":1518,"interventions":1520},"NCT00208000","A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.",[86],"2006-04","2004-07",[1519],"\"Hyperuricemia,Anserine\"",[1497],{"trials":1522,"activeCount":97},[],{"trials":1524,"activeCount":97},[],{"trials":1526,"activeCount":97},[],{"intervention":1528,"totalTrials":93,"cells":1529},"PG2",{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1534,"PHASE3":1546,"PHASE4":1548,"NA":1550},{"trials":1531,"activeCount":97},[],{"trials":1533,"activeCount":97},[],{"trials":1535,"activeCount":97},[1536],{"nctId":1537,"briefTitle":1538,"status":267,"phases":1539,"primaryCompletion":1540,"completion":1540,"start":1541,"enrollment":1542,"conditions":1543,"interventions":1545},"NCT01603667","PG2 Injection 500 mg in Acute Stroke Study (Pass)",[86],"2015-10","2012-06",86,[1544],"Acute Stroke",[1528],{"trials":1547,"activeCount":97},[],{"trials":1549,"activeCount":97},[],{"trials":1551,"activeCount":97},[],{"intervention":1553,"totalTrials":93,"cells":1554},"nitric oxide gel",{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1570,"PHASE4":1572,"NA":1574},{"trials":1556,"activeCount":97},[],{"trials":1558,"activeCount":97},[],{"trials":1560,"activeCount":97},[1561],{"nctId":1562,"briefTitle":1563,"status":267,"phases":1564,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":307,"conditions":1567,"interventions":1569},"NCT01633086","A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy",[86],"2013-02","2012-07",[1568],"Neuropathic Pain",[1553],{"trials":1571,"activeCount":97},[],{"trials":1573,"activeCount":97},[],{"trials":1575,"activeCount":97},[],{"intervention":1577,"totalTrials":93,"cells":1578},"DAAOI-1",{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1580,"activeCount":97},[],{"trials":1582,"activeCount":97},[],{"trials":1584,"activeCount":97},[1585],{"nctId":1586,"briefTitle":1587,"status":267,"phases":1588,"primaryCompletion":1589,"completion":1589,"start":974,"enrollment":225,"conditions":1590,"interventions":1591},"NCT01390376","DAAOI-1 Treatment for Treatment-resistant Schizophrenia",[86],"2014-09",[15],[1577,1577],{"trials":1593,"activeCount":97},[],{"trials":1595,"activeCount":97},[],{"trials":1597,"activeCount":97},[],{"intervention":1599,"totalTrials":93,"cells":1600},"Sarcosine and D-serine",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1615,"PHASE4":1617,"NA":1619},{"trials":1602,"activeCount":97},[],{"trials":1604,"activeCount":97},[],{"trials":1606,"activeCount":97},[1607],{"nctId":1608,"briefTitle":1609,"status":267,"phases":1610,"completion":1611,"start":1612,"enrollment":225,"conditions":1613,"interventions":1614},"NCT00491569","Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia",[86],"2006-12","2005-01",[1473,1474,1475,1476],[1599],{"trials":1616,"activeCount":97},[],{"trials":1618,"activeCount":97},[],{"trials":1620,"activeCount":97},[],{"intervention":1622,"totalTrials":93,"cells":1623},"docetaxel, cisplatin, fluorouracil",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1625,"activeCount":97},[],{"trials":1627,"activeCount":97},[],{"trials":1629,"activeCount":97},[1630],{"nctId":1631,"briefTitle":1632,"status":267,"phases":1633,"primaryCompletion":1634,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1640},"NCT04397341","Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck",[86],"2016-08-30","2019-09-15","2014-03-01",58,[1639],"Locally Advanced Head and Neck Carcinoma",[1622],{"trials":1642,"activeCount":97},[],{"trials":1644,"activeCount":97},[],{"trials":1646,"activeCount":97},[],{"intervention":1205,"totalTrials":93,"cells":1648},{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1659,"PHASE4":1661,"NA":1663},{"trials":1650,"activeCount":97},[],{"trials":1652,"activeCount":97},[],{"trials":1654,"activeCount":97},[1655],{"nctId":1195,"briefTitle":1196,"status":796,"phases":1656,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":225,"conditions":1657,"interventions":1658},[86],[1201,1202,1203],[1205,1206,1186],{"trials":1660,"activeCount":97},[],{"trials":1662,"activeCount":97},[],{"trials":1664,"activeCount":97},[],{"intervention":1206,"totalTrials":93,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1677,"PHASE4":1679,"NA":1681},{"trials":1668,"activeCount":97},[],{"trials":1670,"activeCount":97},[],{"trials":1672,"activeCount":97},[1673],{"nctId":1195,"briefTitle":1196,"status":796,"phases":1674,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":225,"conditions":1675,"interventions":1676},[86],[1201,1202,1203],[1205,1206,1186],{"trials":1678,"activeCount":97},[],{"trials":1680,"activeCount":97},[],{"trials":1682,"activeCount":97},[],{"intervention":1684,"totalTrials":93,"cells":1685},"paper mulberry leaf",{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1687,"activeCount":97},[],{"trials":1689,"activeCount":97},[],{"trials":1691,"activeCount":97},[1692],{"nctId":1693,"briefTitle":1694,"status":796,"phases":1695,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":559,"conditions":1699,"interventions":1701},"NCT04117919","Psoriasis、Indigo Naturalis、Chinese Medicine Medicated Bath",[86],"2019-12-31","2020-03-03","2019-10-05",[1700],"Psoriasis",[1684,1702],"Triamcinolone (Encort-A) 0.1%15g\u002FTube",{"trials":1704,"activeCount":97},[],{"trials":1706,"activeCount":97},[],{"trials":1708,"activeCount":97},[],{"intervention":1702,"totalTrials":93,"cells":1710},{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1712,"activeCount":97},[],{"trials":1714,"activeCount":97},[],{"trials":1716,"activeCount":97},[1717],{"nctId":1693,"briefTitle":1694,"status":796,"phases":1718,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":559,"conditions":1719,"interventions":1720},[86],[1700],[1684,1702],{"trials":1722,"activeCount":97},[],{"trials":1724,"activeCount":97},[],{"trials":1726,"activeCount":97},[],{"intervention":1728,"totalTrials":93,"cells":1729},"GlyT-1 inhibitor-1",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1731,"activeCount":97},[],{"trials":1733,"activeCount":97},[],{"trials":1735,"activeCount":97},[1736],{"nctId":1737,"briefTitle":1738,"status":267,"phases":1739,"primaryCompletion":1740,"completion":1740,"start":1741,"enrollment":880,"conditions":1742,"interventions":1744},"NCT01251055","GlyT-1 Inhibitor Treatment for Refractory Schizophrenia",[86],"2013-10","2010-04",[15,1743],"Treatment Refractory",[1728],{"trials":1746,"activeCount":97},[],{"trials":1748,"activeCount":97},[],{"trials":1750,"activeCount":97},[],{"intervention":1752,"totalTrials":93,"cells":1753},"DAAOI-2",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1755,"activeCount":97},[],{"trials":1757,"activeCount":97},[],{"trials":1759,"activeCount":97},[1760],{"nctId":1761,"briefTitle":1762,"status":267,"phases":1763,"primaryCompletion":1357,"completion":1357,"start":1764,"enrollment":880,"conditions":1765,"interventions":1766},"NCT02532686","DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia",[86],"2014-10",[15],[1752],{"trials":1768,"activeCount":97},[],{"trials":1770,"activeCount":97},[],{"trials":1772,"activeCount":97},[],{"intervention":1774,"totalTrials":93,"cells":1775},"TZD",{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1777,"activeCount":97},[],{"trials":1779,"activeCount":97},[],{"trials":1781,"activeCount":97},[1782],{"nctId":1783,"briefTitle":1784,"status":267,"phases":1785,"primaryCompletion":1786,"completion":1786,"start":1516,"enrollment":1787,"conditions":1788,"interventions":1790},"NCT01577095","Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy",[86],"2007-05",49,[1789],"Type 2 Diabetes Mellitus With Features of Insulin Resistance",[1774],{"trials":1792,"activeCount":97},[],{"trials":1794,"activeCount":97},[],{"trials":1796,"activeCount":97},[],{"intervention":1798,"totalTrials":93,"cells":1799},"Single arm, open-label",{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1816,"PHASE4":1818,"NA":1820},{"trials":1801,"activeCount":97},[],{"trials":1803,"activeCount":97},[],{"trials":1805,"activeCount":97},[1806],{"nctId":1807,"briefTitle":1808,"status":796,"phases":1809,"primaryCompletion":771,"completion":1810,"start":1811,"enrollment":176,"conditions":1812,"interventions":1815},"NCT02772094","Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)",[86],"2016-12","2005-05",[1813,1814],"Glioblastoma Multiforme","Glioblastoma",[1798],{"trials":1817,"activeCount":97},[],{"trials":1819,"activeCount":97},[],{"trials":1821,"activeCount":97},[],{"intervention":1823,"totalTrials":93,"cells":1824},"N-methyl glycine",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1829,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1826,"activeCount":97},[],{"trials":1828,"activeCount":97},[],{"trials":1830,"activeCount":97},[1831],{"nctId":1832,"briefTitle":1833,"status":267,"phases":1834,"primaryCompletion":1835,"start":1836,"enrollment":559,"conditions":1837,"interventions":1839},"NCT01031927","N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)",[86],"2009-02","2007-06",[1838],"Obsessive Compulsive Disorder",[1823],{"trials":1841,"activeCount":97},[],{"trials":1843,"activeCount":97},[],{"trials":1845,"activeCount":97},[],{"intervention":1847,"totalTrials":93,"cells":1848},"escitalopram",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1850,"activeCount":97},[],{"trials":1852,"activeCount":97},[],{"trials":1854,"activeCount":97},[1855],{"nctId":1856,"briefTitle":1857,"status":1129,"phases":1858,"primaryCompletion":1859,"completion":1859,"start":1860,"enrollment":143,"conditions":1861,"interventions":1863},"NCT03010761","Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer",[86],"2018-01-31","2016-01-14",[1862],"Addiction",[1847,1864],"Moclobemide",{"trials":1866,"activeCount":97},[],{"trials":1868,"activeCount":97},[],{"trials":1870,"activeCount":97},[],{"intervention":1864,"totalTrials":93,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1874,"activeCount":97},[],{"trials":1876,"activeCount":97},[],{"trials":1878,"activeCount":97},[1879],{"nctId":1856,"briefTitle":1857,"status":1129,"phases":1880,"primaryCompletion":1859,"completion":1859,"start":1860,"enrollment":143,"conditions":1881,"interventions":1882},[86],[1862],[1847,1864],{"trials":1884,"activeCount":97},[],{"trials":1886,"activeCount":97},[],{"trials":1888,"activeCount":97},[],{"intervention":1890,"totalTrials":93,"cells":1891},"Danggui Buxue Tang",{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1893,"activeCount":97},[],{"trials":1895,"activeCount":97},[],{"trials":1897,"activeCount":97},[1898],{"nctId":1899,"briefTitle":1900,"status":796,"phases":1901,"primaryCompletion":1902,"completion":1902,"start":1903,"enrollment":1427,"conditions":1904,"interventions":1906},"NCT03578575","To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma",[86],"2020-07-31","2018-07-26",[1905],"Nasopharyngeal Carcinoma",[1890],{"trials":1908,"activeCount":97},[],{"trials":1910,"activeCount":97},[],{"trials":1912,"activeCount":97},[],{"intervention":1914,"totalTrials":93,"cells":1915},"Surfactant",{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1917,"activeCount":97},[],{"trials":1919,"activeCount":97},[],{"trials":1921,"activeCount":97},[1922],{"nctId":1923,"briefTitle":1924,"status":796,"phases":1925,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":225,"conditions":1928,"interventions":1929},"NCT01723683","Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS",[86],"2013-01","2012-02",[1134],[1914],{"trials":1931,"activeCount":97},[],{"trials":1933,"activeCount":97},[],{"trials":1935,"activeCount":97},[],{"intervention":1937,"totalTrials":93,"cells":1938},"Lapatinib",{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1940,"activeCount":97},[],{"trials":1942,"activeCount":97},[],{"trials":1944,"activeCount":97},[1945],{"nctId":1946,"briefTitle":1947,"status":1129,"phases":1948,"primaryCompletion":1589,"completion":1589,"start":1566,"enrollment":1949,"conditions":1950,"interventions":1952},"NCT01658358","ErbB2 Positive Metastatic Breast Cancer",[85,86],15,[1951],"Metastatic Breast Cancer",[1937,1953],"Lipo-Dox",{"trials":1955,"activeCount":97},[],{"trials":1957,"activeCount":97},[],{"trials":1959,"activeCount":97},[],{"intervention":1953,"totalTrials":93,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1963,"activeCount":97},[],{"trials":1965,"activeCount":97},[],{"trials":1967,"activeCount":97},[1968],{"nctId":1946,"briefTitle":1947,"status":1129,"phases":1969,"primaryCompletion":1589,"completion":1589,"start":1566,"enrollment":1949,"conditions":1970,"interventions":1971},[85,86],[1951],[1937,1953],{"trials":1973,"activeCount":97},[],{"trials":1975,"activeCount":97},[],{"trials":1977,"activeCount":97},[],{"intervention":1979,"totalTrials":93,"cells":1980},"Indigo naturalis ointment",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1982,"activeCount":97},[],{"trials":1984,"activeCount":97},[],{"trials":1986,"activeCount":97},[1987],{"nctId":1988,"briefTitle":1989,"status":267,"phases":1990,"primaryCompletion":1991,"completion":1991,"start":1565,"enrollment":307,"conditions":1992,"interventions":1993},"NCT01901705","A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis",[86],"2014-01",[1700],[1979],{"trials":1995,"activeCount":97},[],{"trials":1997,"activeCount":97},[],{"trials":1999,"activeCount":97},[],{"intervention":2001,"totalTrials":93,"cells":2002},"Chinese Medicine",{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2019,"PHASE4":2021,"NA":2023},{"trials":2004,"activeCount":97},[],{"trials":2006,"activeCount":97},[],{"trials":2008,"activeCount":97},[2009],{"nctId":2010,"briefTitle":2011,"status":796,"phases":2012,"primaryCompletion":2013,"completion":2013,"start":2013,"enrollment":2014,"conditions":2015,"interventions":2017},"NCT01682551","Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness",[86],"2012-09",240,[2016],"Acute Mountain Sickness (AMS)",[2001,2018],"Acetalozamide",{"trials":2020,"activeCount":97},[],{"trials":2022,"activeCount":97},[],{"trials":2024,"activeCount":97},[],{"intervention":2018,"totalTrials":93,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2028,"activeCount":97},[],{"trials":2030,"activeCount":97},[],{"trials":2032,"activeCount":97},[2033],{"nctId":2010,"briefTitle":2011,"status":796,"phases":2034,"primaryCompletion":2013,"completion":2013,"start":2013,"enrollment":2014,"conditions":2035,"interventions":2036},[86],[2016],[2001,2018],{"trials":2038,"activeCount":97},[],{"trials":2040,"activeCount":97},[],{"trials":2042,"activeCount":97},[],{"intervention":2044,"totalTrials":93,"cells":2045},"D-amino acid oxidase inhibition",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2047,"activeCount":97},[],{"trials":2049,"activeCount":97},[],{"trials":2051,"activeCount":97},[2052],{"nctId":2053,"briefTitle":2054,"status":267,"phases":2055,"primaryCompletion":1482,"completion":1482,"start":1483,"enrollment":2056,"conditions":2057,"interventions":2058},"NCT00960219","D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia",[86],52,[1473,1474,1475,1476],[2044],{"trials":2060,"activeCount":97},[],{"trials":2062,"activeCount":97},[],{"trials":2064,"activeCount":97},[],{"intervention":2066,"totalTrials":93,"cells":2067},"SS-1",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2069,"activeCount":97},[],{"trials":2071,"activeCount":97},[],{"trials":2073,"activeCount":97},[2074],{"nctId":2075,"briefTitle":2076,"status":796,"phases":2077,"primaryCompletion":2078,"completion":1356,"start":2079,"enrollment":143,"conditions":2080,"interventions":2082},"NCT02855658","Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome",[86],"2016-10","2014-02",[2081],"Sjögren's Syndrome",[2066],{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[],{"trials":2088,"activeCount":97},[],{"intervention":2090,"totalTrials":93,"cells":2091},"Chinese medical treatment-LCH1",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2093,"activeCount":97},[],{"trials":2095,"activeCount":97},[],{"trials":2097,"activeCount":97},[2098],{"nctId":2099,"briefTitle":2100,"status":796,"phases":2101,"primaryCompletion":2102,"completion":2102,"start":2103,"enrollment":2104,"conditions":2105,"interventions":2107},"NCT01359501","Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients",[86],"2012-12","2011-05",100,[2106,20],"Leucopenia",[2090],{"trials":2109,"activeCount":97},[],{"trials":2111,"activeCount":97},[],{"trials":2113,"activeCount":97},[],{"intervention":2115,"totalTrials":93,"cells":2116},"Bu-Yang-Huan-Wu Tang",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2130,"PHASE4":2132,"NA":2134},{"trials":2118,"activeCount":97},[],{"trials":2120,"activeCount":97},[],{"trials":2122,"activeCount":97},[2123],{"nctId":2124,"briefTitle":2125,"status":796,"phases":2126,"primaryCompletion":1810,"completion":1810,"start":2127,"enrollment":1427,"conditions":2128,"interventions":2129},"NCT02150252","Evaluate the Efficacy of Bu-Yang- Huan-Wu Tang（BYHWT）on Ischemic Stroke",[86],"2014-05",[32],[2115],{"trials":2131,"activeCount":97},[],{"trials":2133,"activeCount":97},[],{"trials":2135,"activeCount":97},[],{"intervention":2137,"totalTrials":93,"cells":2138},"recombinant human erythropoietin",{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2157,"PHASE4":2159,"NA":2161},{"trials":2140,"activeCount":97},[],{"trials":2142,"activeCount":97},[],{"trials":2144,"activeCount":97},[2145],{"nctId":2146,"briefTitle":2147,"status":796,"phases":2148,"primaryCompletion":1482,"completion":1482,"start":2149,"enrollment":2104,"conditions":2150,"interventions":2155},"NCT00910234","Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants",[85,86],"2009-08",[2151,2152,2153,2154],"Infant, Premature","Leukomalacia, Periventricular","Intraventricular Hemorrhage","Retinopathy of Prematurity",[2137,2137,2156],"Normal saline",{"trials":2158,"activeCount":97},[],{"trials":2160,"activeCount":97},[],{"trials":2162,"activeCount":97},[],{"intervention":2156,"totalTrials":93,"cells":2164},{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2175,"PHASE4":2177,"NA":2179},{"trials":2166,"activeCount":97},[],{"trials":2168,"activeCount":97},[],{"trials":2170,"activeCount":97},[2171],{"nctId":2146,"briefTitle":2147,"status":796,"phases":2172,"primaryCompletion":1482,"completion":1482,"start":2149,"enrollment":2104,"conditions":2173,"interventions":2174},[85,86],[2151,2152,2153,2154],[2137,2137,2156],{"trials":2176,"activeCount":97},[],{"trials":2178,"activeCount":97},[],{"trials":2180,"activeCount":97},[],{"intervention":2182,"totalTrials":93,"cells":2183},"Celecoxib",{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2200,"PHASE4":2202,"NA":2204},{"trials":2185,"activeCount":97},[],{"trials":2187,"activeCount":97},[],{"trials":2189,"activeCount":97},[2190],{"nctId":2191,"briefTitle":2192,"status":796,"phases":2193,"primaryCompletion":1810,"completion":2194,"start":2195,"enrollment":2196,"conditions":2197,"interventions":2199},"NCT02739204","Concurrent Radiotherapy and\u002For Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma",[86],"2017-12","2013-11",270,[2198],"Oral Squamous Cell Carcinoma",[2182],{"trials":2201,"activeCount":97},[],{"trials":2203,"activeCount":97},[],{"trials":2205,"activeCount":97},[],{"intervention":2207,"totalTrials":93,"cells":2208},"Nitric Oxide",{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2222,"PHASE4":2224,"NA":2226},{"trials":2210,"activeCount":97},[],{"trials":2212,"activeCount":97},[],{"trials":2214,"activeCount":97},[2215],{"nctId":2216,"briefTitle":2217,"status":796,"phases":2218,"primaryCompletion":973,"completion":973,"start":1566,"enrollment":880,"conditions":2219,"interventions":2221},"NCT01351493","Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Pressure Sore",[85,86],[2220],"Pressure Ulcer",[2207],{"trials":2223,"activeCount":97},[],{"trials":2225,"activeCount":97},[],{"trials":2227,"activeCount":97},[],{"intervention":2229,"totalTrials":93,"cells":2230},"convention therapy",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2245,"PHASE4":2247,"NA":2249},{"trials":2232,"activeCount":97},[],{"trials":2234,"activeCount":97},[],{"trials":2236,"activeCount":97},[2237],{"nctId":2238,"briefTitle":2239,"status":267,"phases":2240,"primaryCompletion":821,"completion":821,"start":2241,"enrollment":559,"conditions":2242,"interventions":2244},"NCT00950521","Efficacy Study of CD34 Stem Cell in Chronic Stroke Patients",[86],"2009-06",[18,2243],"Middle Cerebral Artery Infarction",[2229],{"trials":2246,"activeCount":97},[],{"trials":2248,"activeCount":97},[],{"trials":2250,"activeCount":97},[],{"intervention":2252,"totalTrials":93,"cells":2253},"iv ibuprofen",{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2273,"PHASE4":2275,"NA":2277},{"trials":2255,"activeCount":97},[],{"trials":2257,"activeCount":97},[],{"trials":2259,"activeCount":97},[2260],{"nctId":2261,"briefTitle":2262,"status":796,"phases":2263,"primaryCompletion":1541,"completion":1541,"start":2264,"enrollment":2265,"conditions":2266,"interventions":2271},"NCT01149564","Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants",[85,86],"2009-12",70,[2267,2268,2269,2270],"Extremely Premature Infants","PDA","Oral Ibuprofen","IV Ibuprofen",[2252,2272],"oral ibuprofen",{"trials":2274,"activeCount":97},[],{"trials":2276,"activeCount":97},[],{"trials":2278,"activeCount":97},[],{"intervention":2272,"totalTrials":93,"cells":2280},{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2282,"activeCount":97},[],{"trials":2284,"activeCount":97},[],{"trials":2286,"activeCount":97},[2287],{"nctId":2261,"briefTitle":2262,"status":796,"phases":2288,"primaryCompletion":1541,"completion":1541,"start":2264,"enrollment":2265,"conditions":2289,"interventions":2290},[85,86],[2267,2268,2269,2270],[2252,2272],{"trials":2292,"activeCount":97},[],{"trials":2294,"activeCount":97},[],{"trials":2296,"activeCount":97},[],{"intervention":2298,"totalTrials":93,"cells":2299},"Yigansan",{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2301,"activeCount":97},[],{"trials":2303,"activeCount":97},[],{"trials":2305,"activeCount":97},[2306],{"nctId":2307,"briefTitle":2308,"status":267,"phases":2309,"primaryCompletion":2310,"completion":2311,"start":2312,"enrollment":2313,"conditions":2314,"interventions":2317},"NCT03564132","Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's Disorder",[86],"2020-08-15","2022-08-31","2018-06-16",38,[2315,2316],"Tourette Disorder","Tic Disorders",[2298],{"trials":2319,"activeCount":97},[],{"trials":2321,"activeCount":97},[],{"trials":2323,"activeCount":97},[],{"intervention":1488,"totalTrials":93,"cells":2325},{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2336,"PHASE4":2338,"NA":2340},{"trials":2327,"activeCount":97},[],{"trials":2329,"activeCount":97},[],{"trials":2331,"activeCount":97},[2332],{"nctId":1479,"briefTitle":1480,"status":267,"phases":2333,"primaryCompletion":1482,"completion":1482,"start":1483,"enrollment":880,"conditions":2334,"interventions":2335},[86],[29,1485,1486],[1488,1489],{"trials":2337,"activeCount":97},[],{"trials":2339,"activeCount":97},[],{"trials":2341,"activeCount":97},[],{"intervention":2343,"totalTrials":93,"cells":2344},"DAAOI-P",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2362,"PHASE4":2364,"NA":2366},{"trials":2346,"activeCount":97},[],{"trials":2348,"activeCount":97},[],{"trials":2350,"activeCount":97},[2351],{"nctId":2352,"briefTitle":2353,"status":267,"phases":2354,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":2358,"conditions":2359,"interventions":2361},"NCT04470037","Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder",[86],"2024-12","2025-09","2016-04",61,[2360],"Parkinson's Disease With Dementia",[2343],{"trials":2363,"activeCount":97},[],{"trials":2365,"activeCount":97},[],{"trials":2367,"activeCount":97},[],{"intervention":2369,"totalTrials":93,"cells":2370},"Rituximab",{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2387,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2372,"activeCount":97},[],{"trials":2374,"activeCount":97},[2375],{"nctId":2376,"briefTitle":2377,"status":267,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":285,"conditions":2382,"interventions":2384},"NCT04361409","Rituximab Plus Chemotherapy in Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[85],"2016-11","2017-01","2013-05",[2383],"Head and Neck Squamous Carcinoma",[2369,2385,2386],"Cisplatin","Gemcitabine",{"trials":2388,"activeCount":97},[],{"trials":2390,"activeCount":97},[],{"trials":2392,"activeCount":97},[],{"trials":2394,"activeCount":97},[],{"intervention":2385,"totalTrials":93,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2405,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2398,"activeCount":97},[],{"trials":2400,"activeCount":97},[2401],{"nctId":2376,"briefTitle":2377,"status":267,"phases":2402,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":285,"conditions":2403,"interventions":2404},[85],[2383],[2369,2385,2386],{"trials":2406,"activeCount":97},[],{"trials":2408,"activeCount":97},[],{"trials":2410,"activeCount":97},[],{"trials":2412,"activeCount":97},[],{"intervention":2386,"totalTrials":93,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2416,"activeCount":97},[],{"trials":2418,"activeCount":97},[2419],{"nctId":2376,"briefTitle":2377,"status":267,"phases":2420,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":285,"conditions":2421,"interventions":2422},[85],[2383],[2369,2385,2386],{"trials":2424,"activeCount":97},[],{"trials":2426,"activeCount":97},[],{"trials":2428,"activeCount":97},[],{"trials":2430,"activeCount":97},[],{"intervention":2432,"totalTrials":93,"cells":2433},"ucMSCs",{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2449,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2435,"activeCount":97},[],{"trials":2437,"activeCount":97},[2438],{"nctId":2439,"briefTitle":2440,"status":796,"phases":2441,"primaryCompletion":1541,"completion":1566,"start":2442,"enrollment":285,"conditions":2443,"interventions":2448},"NCT01207869","Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia",[85],"2010-07",[2444,2267,2445,2446,2447],"Bronchopulmonary Dysplasia","Severe BPD That Conventional Therapies Has Failed","No Severe Congenital Anomalies","no Severe IVH Neither Cystic PVL",[2432],{"trials":2450,"activeCount":97},[],{"trials":2452,"activeCount":97},[],{"trials":2454,"activeCount":97},[],{"trials":2456,"activeCount":97},[],{"intervention":2458,"totalTrials":93,"cells":2459},"SZKJT",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2476,"PHASE3":2478,"PHASE4":2480,"NA":2482},{"trials":2461,"activeCount":97},[],{"trials":2463,"activeCount":97},[2464],{"nctId":2465,"briefTitle":2466,"status":267,"phases":2467,"primaryCompletion":2468,"completion":2469,"start":2470,"enrollment":2471,"conditions":2472,"interventions":2475},"NCT05590650","A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients",[85],"2020-06-14","2020-12-25","2018-07-07",21,[2473,2474],"Head and Neck Neoplasm","Chemoradiotherapy",[2458],{"trials":2477,"activeCount":97},[],{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[],{"trials":2483,"activeCount":97},[],{"intervention":2485,"totalTrials":93,"cells":2486},"Cordyceps cicadae extract",{"EARLY_PHASE1":2487,"PHASE1":2499,"PHASE2":2501,"PHASE3":2503,"PHASE4":2505,"NA":2507},{"trials":2488,"activeCount":97},[2489],{"nctId":2490,"briefTitle":2491,"status":267,"phases":2492,"primaryCompletion":2493,"completion":2494,"start":2495,"enrollment":225,"conditions":2496,"interventions":2498},"NCT05778409","To Study the Effects of Cordyceps Cicadae on Vision Care",[84],"2023-04-14","2023-08-31","2023-03-08",[2497],"Myopia",[2485],{"trials":2500,"activeCount":97},[],{"trials":2502,"activeCount":97},[],{"trials":2504,"activeCount":97},[],{"trials":2506,"activeCount":97},[],{"trials":2508,"activeCount":97},[],{"intervention":2510,"totalTrials":93,"cells":2511},"Baby Drink group",{"EARLY_PHASE1":2512,"PHASE1":2520,"PHASE2":2522,"PHASE3":2524,"PHASE4":2526,"NA":2528},{"trials":2513,"activeCount":97},[2514],{"nctId":2515,"briefTitle":2516,"status":796,"phases":2517,"primaryCompletion":1263,"completion":1263,"start":2495,"enrollment":225,"conditions":2518,"interventions":2519},"NCT05778201","To Study the Effects of Baby Drink on Vision Care",[84],[2497],[2510],{"trials":2521,"activeCount":97},[],{"trials":2523,"activeCount":97},[],{"trials":2525,"activeCount":97},[],{"trials":2527,"activeCount":97},[],{"trials":2529,"activeCount":97},[],{"intervention":2531,"totalTrials":93,"cells":2532},"Buyang Huanwu Decoction",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2541,"NA":2543},{"trials":2534,"activeCount":97},[],{"trials":2536,"activeCount":97},[],{"trials":2538,"activeCount":97},[],{"trials":2540,"activeCount":97},[],{"trials":2542,"activeCount":97},[],{"trials":2544,"activeCount":97},[2545],{"nctId":2546,"briefTitle":2547,"status":796,"phases":2548,"primaryCompletion":2549,"completion":2550,"start":2551,"enrollment":225,"conditions":2552,"interventions":2556},"NCT06054763","Buyang Huanwu Decoction and Normal Tension Glaucoma",[89],"2024-10-31","2024-12-31","2023-10-01",[2553,2554,2555,2001],"Glaucoma","Visual Acuity","Visual Field",[2531],{"intervention":2558,"totalTrials":93,"cells":2559},"DFX",{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2564,"PHASE3":2566,"PHASE4":2568,"NA":2570},{"trials":2561,"activeCount":97},[],{"trials":2563,"activeCount":97},[],{"trials":2565,"activeCount":97},[],{"trials":2567,"activeCount":97},[],{"trials":2569,"activeCount":97},[],{"trials":2571,"activeCount":97},[2572],{"nctId":2573,"briefTitle":2574,"status":267,"phases":2575,"primaryCompletion":2576,"start":2577,"enrollment":9,"conditions":2578,"interventions":2580},"NCT02198508","Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients",[89],"2008-07","2007-07",[2579],"Beta-thalassemia Major",[2558,2581],"DFP",{"intervention":2581,"totalTrials":93,"cells":2583},{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2585,"activeCount":97},[],{"trials":2587,"activeCount":97},[],{"trials":2589,"activeCount":97},[],{"trials":2591,"activeCount":97},[],{"trials":2593,"activeCount":97},[],{"trials":2595,"activeCount":97},[2596],{"nctId":2573,"briefTitle":2574,"status":267,"phases":2597,"primaryCompletion":2576,"start":2577,"enrollment":9,"conditions":2598,"interventions":2599},[89],[2579],[2558,2581],{"intervention":2601,"totalTrials":93,"cells":2602},"Peginterferon alfa-2a",{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2604,"activeCount":97},[],{"trials":2606,"activeCount":97},[],{"trials":2608,"activeCount":97},[],{"trials":2610,"activeCount":97},[],{"trials":2612,"activeCount":97},[],{"trials":2614,"activeCount":97},[2615],{"nctId":2616,"briefTitle":2617,"status":267,"phases":2618,"primaryCompletion":2619,"completion":2619,"start":822,"enrollment":2620,"conditions":2621,"interventions":2623},"NCT01311947","Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B",[],"2012-03",103,[2622],"Hepatitis B, Chronic",[2601],{"intervention":2625,"totalTrials":93,"cells":2626},"Nuan-gong-ye",{"EARLY_PHASE1":2627,"PHASE1":2629,"PHASE2":2631,"PHASE3":2633,"PHASE4":2635,"NA":2637},{"trials":2628,"activeCount":97},[],{"trials":2630,"activeCount":97},[],{"trials":2632,"activeCount":97},[],{"trials":2634,"activeCount":97},[],{"trials":2636,"activeCount":97},[],{"trials":2638,"activeCount":97},[2639],{"nctId":2640,"briefTitle":2641,"status":796,"phases":2642,"primaryCompletion":2643,"completion":269,"start":2644,"enrollment":8,"conditions":2645,"interventions":2647},"NCT06295822","The Effectiveness of Chinese Medicine Nuan-gong-ye on Primary Dysmenorrhea",[89],"2025-08-31","2024-03-04",[2001,2646],"Primary Dysmenorrhea",[2625],{"intervention":2649,"totalTrials":93,"cells":2650},"Exposure to sedative-hypnotic drugs",{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2657,"PHASE4":2659,"NA":2661},{"trials":2652,"activeCount":97},[],{"trials":2654,"activeCount":97},[],{"trials":2656,"activeCount":97},[],{"trials":2658,"activeCount":97},[],{"trials":2660,"activeCount":97},[],{"trials":2662,"activeCount":97},[2663],{"nctId":2664,"briefTitle":2665,"status":796,"phases":2666,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":2670,"conditions":2671,"interventions":2673},"NCT02648776","Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly",[],"2018-01","2018-12","2016-01",1400,[2672],"Sleep Disorders",[2649],{"intervention":2675,"totalTrials":93,"cells":2676},"BXD treatment",{"EARLY_PHASE1":2677,"PHASE1":2679,"PHASE2":2681,"PHASE3":2683,"PHASE4":2685,"NA":2687},{"trials":2678,"activeCount":97},[],{"trials":2680,"activeCount":97},[],{"trials":2682,"activeCount":97},[],{"trials":2684,"activeCount":97},[],{"trials":2686,"activeCount":97},[],{"trials":2688,"activeCount":97},[2689],{"nctId":2690,"briefTitle":2691,"status":267,"phases":2692,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":367,"conditions":2695,"interventions":2697},"NCT07035613","Investigating Chinese Herbal Medicine for Modulating Gut Microbiota in Treating Inflammatory Bowel Disease: Molecular Mechanisms and Clinical Study",[89],"2025-06-06","2024-02-27",[2696],"IBD - Inflammatory Bowel Disease",[2675],{"intervention":2699,"totalTrials":93,"cells":2700},"western medicine",{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2705,"PHASE3":2707,"PHASE4":2709,"NA":2711},{"trials":2702,"activeCount":97},[],{"trials":2704,"activeCount":97},[],{"trials":2706,"activeCount":97},[],{"trials":2708,"activeCount":97},[],{"trials":2710,"activeCount":97},[],{"trials":2712,"activeCount":97},[2713],{"nctId":2714,"briefTitle":2715,"status":796,"phases":2716,"primaryCompletion":2717,"completion":2718,"start":2719,"enrollment":225,"conditions":2720,"interventions":2722},"NCT04621513","Collaborative Care Model for Allergic Rhinitis With Obstructive Sleep Apnea From Prevention to Treatment.",[89],"2021-12-16","2022-12-31","2020-07-29",[2721],"Pediatric Sleep Apnea",[2699],{"intervention":2724,"totalTrials":93,"cells":2725},"House dust mite",{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2730,"PHASE3":2732,"PHASE4":2734,"NA":2736},{"trials":2727,"activeCount":97},[],{"trials":2729,"activeCount":97},[],{"trials":2731,"activeCount":97},[],{"trials":2733,"activeCount":97},[],{"trials":2735,"activeCount":97},[],{"trials":2737,"activeCount":97},[2738],{"nctId":2739,"briefTitle":2740,"status":2741,"phases":2742,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":97,"conditions":2745,"interventions":2747},"NCT03307278","House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance","WITHDRAWN",[89],"2018-09-06","2017-11-30",[2746],"Allergic Asthma",[2724],{"intervention":2749,"totalTrials":93,"cells":2750},"Siwu Tang",{"EARLY_PHASE1":2751,"PHASE1":2753,"PHASE2":2755,"PHASE3":2757,"PHASE4":2759,"NA":2761},{"trials":2752,"activeCount":97},[],{"trials":2754,"activeCount":97},[],{"trials":2756,"activeCount":97},[],{"trials":2758,"activeCount":97},[],{"trials":2760,"activeCount":97},[],{"trials":2762,"activeCount":97},[2763],{"nctId":2764,"briefTitle":2765,"status":796,"phases":2766,"primaryCompletion":1566,"completion":949,"start":2442,"enrollment":136,"conditions":2767,"interventions":2770},"NCT01221662","Efficiency Study of Siwu Tang to Treat Brain Hypoperfusion Syndrome",[89],[2768,2769],"Brain Hypoperfusion Syndrome","Ischemia Brain",[2749],{"intervention":2772,"totalTrials":93,"cells":2773},"Chinese Herb",{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2775,"activeCount":97},[],{"trials":2777,"activeCount":97},[],{"trials":2779,"activeCount":97},[],{"trials":2781,"activeCount":97},[],{"trials":2783,"activeCount":97},[],{"trials":2785,"activeCount":97},[2786],{"nctId":2787,"briefTitle":2788,"status":267,"phases":2789,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":2792,"conditions":2793,"interventions":2796},"NCT06393426","The Constitution and Efficacy of Chinese Medicine of Infertility Male, Female, and Pregnant Female",[],"2023-05-31","2023-01-01",37611,[2794,2795],"Infertility","Miscarriage Threatening",[2772],{"intervention":2798,"totalTrials":93,"cells":2799},"Indomethacin and Ibuprofen",{"EARLY_PHASE1":2800,"PHASE1":2802,"PHASE2":2804,"PHASE3":2806,"PHASE4":2808,"NA":2810},{"trials":2801,"activeCount":97},[],{"trials":2803,"activeCount":97},[],{"trials":2805,"activeCount":97},[],{"trials":2807,"activeCount":97},[],{"trials":2809,"activeCount":97},[],{"trials":2811,"activeCount":97},[2812],{"nctId":2813,"briefTitle":2814,"status":1129,"phases":2815,"completion":2816,"start":2817,"enrollment":225,"conditions":2818,"interventions":2821},"NCT00239512","New Management Strategy of PDA for VLBW Preterm Infants",[89],"2006-06","2005-03",[2819,2820],"Ductus Arteriosus, Patent","Preterm Infants",[2798],{"intervention":2823,"totalTrials":93,"cells":2824},"Dinalbuphine sebacate",{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2833,"NA":2835},{"trials":2826,"activeCount":97},[],{"trials":2828,"activeCount":97},[],{"trials":2830,"activeCount":97},[],{"trials":2832,"activeCount":97},[],{"trials":2834,"activeCount":97},[],{"trials":2836,"activeCount":97},[2837],{"nctId":2838,"briefTitle":2839,"status":796,"phases":2840,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":2844,"conditions":2845,"interventions":2848},"NCT06397807","Postoperative Pain Management on Patients Undergoing Lung Tumor Resection",[],"2026-03-02","2026-05-30","2024-05-31",400,[882,2846,2847],"Lung Cancer","Lung Tumor",[2823,2849,2850],"Analgesic injectables","Enteral analgesics",{"intervention":2849,"totalTrials":93,"cells":2852},{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2859,"PHASE4":2861,"NA":2863},{"trials":2854,"activeCount":97},[],{"trials":2856,"activeCount":97},[],{"trials":2858,"activeCount":97},[],{"trials":2860,"activeCount":97},[],{"trials":2862,"activeCount":97},[],{"trials":2864,"activeCount":97},[2865],{"nctId":2838,"briefTitle":2839,"status":796,"phases":2866,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":2844,"conditions":2867,"interventions":2868},[],[882,2846,2847],[2823,2849,2850],{"intervention":2850,"totalTrials":93,"cells":2870},{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2875,"PHASE3":2877,"PHASE4":2879,"NA":2881},{"trials":2872,"activeCount":97},[],{"trials":2874,"activeCount":97},[],{"trials":2876,"activeCount":97},[],{"trials":2878,"activeCount":97},[],{"trials":2880,"activeCount":97},[],{"trials":2882,"activeCount":97},[2883],{"nctId":2838,"briefTitle":2839,"status":796,"phases":2884,"primaryCompletion":2841,"completion":2842,"start":2843,"enrollment":2844,"conditions":2885,"interventions":2886},[],[882,2846,2847],[2823,2849,2850],{"intervention":2888,"totalTrials":93,"cells":2889},"sugammadex",{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2894,"PHASE3":2896,"PHASE4":2898,"NA":2900},{"trials":2891,"activeCount":97},[],{"trials":2893,"activeCount":97},[],{"trials":2895,"activeCount":97},[],{"trials":2897,"activeCount":97},[],{"trials":2899,"activeCount":97},[],{"trials":2901,"activeCount":97},[2902],{"nctId":2903,"briefTitle":2904,"status":267,"phases":2905,"primaryCompletion":2494,"completion":2494,"start":2906,"enrollment":2907,"conditions":2908,"interventions":2914},"NCT06632067","Sugammadex and Time to Extubation in Ophthalmic Surgery",[],"2023-08-01",262,[2909,2910,2911,2912,2913],"General Anesthesia Using Endotracheal Intubation","Ophthalmologic Surgical Procedure","Sugammadex","Neostigmine","Extubation Readiness",[2888,2915],"Neostigmine + Atropine",{"intervention":2915,"totalTrials":93,"cells":2917},{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2924,"PHASE4":2926,"NA":2928},{"trials":2919,"activeCount":97},[],{"trials":2921,"activeCount":97},[],{"trials":2923,"activeCount":97},[],{"trials":2925,"activeCount":97},[],{"trials":2927,"activeCount":97},[],{"trials":2929,"activeCount":97},[2930],{"nctId":2903,"briefTitle":2904,"status":267,"phases":2931,"primaryCompletion":2494,"completion":2494,"start":2906,"enrollment":2907,"conditions":2932,"interventions":2933},[],[2909,2910,2911,2912,2913],[2888,2915],{"intervention":2935,"totalTrials":93,"cells":2936},"Conventional drug therapy",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2938,"activeCount":97},[],{"trials":2940,"activeCount":97},[],{"trials":2942,"activeCount":97},[],{"trials":2944,"activeCount":97},[],{"trials":2946,"activeCount":97},[],{"trials":2948,"activeCount":97},[2949],{"nctId":2950,"briefTitle":2951,"status":796,"phases":2952,"primaryCompletion":2953,"completion":2953,"start":2954,"enrollment":136,"conditions":2955,"interventions":2957},"NCT04467528","Electroacupuncture for Gastrointestinal Dysmotility After Abdominal Surgery",[89],"2021-03-31","2020-04-27",[2956],"Abdominal Surgery",[2935],{"intervention":2959,"totalTrials":93,"cells":2960},"Metoclopramide 10mg",{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2962,"activeCount":97},[],{"trials":2964,"activeCount":97},[],{"trials":2966,"activeCount":97},[],{"trials":2968,"activeCount":97},[],{"trials":2970,"activeCount":97},[],{"trials":2972,"activeCount":97},[2973],{"nctId":2974,"briefTitle":2975,"status":267,"phases":2976,"primaryCompletion":2977,"completion":2977,"start":2978,"enrollment":1383,"conditions":2979,"interventions":2982},"NCT03934294","Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients",[89],"2021-03-19","2019-05-15",[2980,2981],"Oral Cancer","Hypopharyngeal Cancer",[2959],{"intervention":2984,"totalTrials":93,"cells":2985},"Diclofenac",{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":2992,"PHASE4":2994,"NA":2996},{"trials":2987,"activeCount":97},[],{"trials":2989,"activeCount":97},[],{"trials":2991,"activeCount":97},[],{"trials":2993,"activeCount":97},[],{"trials":2995,"activeCount":97},[],{"trials":2997,"activeCount":97},[2998],{"nctId":2999,"briefTitle":3000,"status":267,"phases":3001,"primaryCompletion":1312,"completion":1312,"start":3002,"enrollment":3003,"conditions":3004,"interventions":3005},"NCT04511832","Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors",[89],"2018-03-28",54,[20],[2984],{"intervention":3007,"totalTrials":93,"cells":3008},"Dexmedetomidine",{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3013,"PHASE3":3015,"PHASE4":3017,"NA":3019},{"trials":3010,"activeCount":97},[],{"trials":3012,"activeCount":97},[],{"trials":3014,"activeCount":97},[],{"trials":3016,"activeCount":97},[],{"trials":3018,"activeCount":97},[],{"trials":3020,"activeCount":97},[3021],{"nctId":3022,"briefTitle":3023,"status":267,"phases":3024,"primaryCompletion":3025,"completion":3025,"start":3026,"enrollment":3027,"conditions":3028,"interventions":3034},"NCT07249164","Perioperative Dexmedetomidine and 30-Day Outcomes After Adult Cardiac Surgery",[],"2025-07-31","2010-01-01",408153,[3029,3030,3031,3032,3033],"Delirium - Postoperative","Cardiac Surgical Procedures","Coronary Artery Bypass Graft (CABG)","Valve Surgery","Postoperative Complications",[3007],{"intervention":3036,"totalTrials":93,"cells":3037},"Valerian",{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3044,"PHASE4":3046,"NA":3048},{"trials":3039,"activeCount":97},[],{"trials":3041,"activeCount":97},[],{"trials":3043,"activeCount":97},[],{"trials":3045,"activeCount":97},[],{"trials":3047,"activeCount":97},[],{"trials":3049,"activeCount":97},[3050],{"nctId":3051,"briefTitle":3052,"status":796,"phases":3053,"primaryCompletion":3054,"completion":3054,"start":3055,"enrollment":2104,"conditions":3056,"interventions":3059},"NCT05185219","The Effect of Valerian on Insomnia in Menopausal Women",[89],"2025-01-20","2021-12-14",[3057,3058],"Menopausal Women","Insomnia",[3036],{"intervention":3061,"totalTrials":93,"cells":3062},"antihistamine",{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3067,"PHASE3":3069,"PHASE4":3071,"NA":3073},{"trials":3064,"activeCount":97},[],{"trials":3066,"activeCount":97},[],{"trials":3068,"activeCount":97},[],{"trials":3070,"activeCount":97},[],{"trials":3072,"activeCount":97},[],{"trials":3074,"activeCount":97},[3075],{"nctId":3076,"briefTitle":3077,"status":267,"phases":3078,"primaryCompletion":3079,"completion":3080,"start":3081,"enrollment":880,"conditions":3082,"interventions":3084},"NCT03805035","Anti-histamines Promote Electroacupuncture Analgesia: Basic and Clinical Research",[89],"2019-06-27","2019-06-30","2019-01-24",[3083],"Pain",[3061,3061],{"intervention":3086,"totalTrials":93,"cells":3087},"caffeinated chewing gum",{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3089,"activeCount":97},[],{"trials":3091,"activeCount":97},[],{"trials":3093,"activeCount":97},[],{"trials":3095,"activeCount":97},[],{"trials":3097,"activeCount":97},[],{"trials":3099,"activeCount":97},[3100],{"nctId":3101,"briefTitle":3102,"status":267,"phases":3103,"primaryCompletion":3104,"completion":3105,"start":3106,"enrollment":3107,"conditions":3108,"interventions":3111},"NCT06693505","The Effect of Caffeinated Chewing Gum on Cognitive Performance in Night-shift Emergency Physicians",[89],"2024-08-25","2024-08-31","2022-10-01",14,[3109,3110],"Cognitive Performance","Sleep Quality",[3086],{"intervention":3113,"totalTrials":93,"cells":3114},"CM",{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3116,"activeCount":97},[],{"trials":3118,"activeCount":97},[],{"trials":3120,"activeCount":97},[],{"trials":3122,"activeCount":97},[],{"trials":3124,"activeCount":97},[],{"trials":3126,"activeCount":97},[3127],{"nctId":3128,"briefTitle":3129,"status":796,"phases":3130,"primaryCompletion":2494,"completion":3131,"start":3132,"enrollment":1542,"conditions":3133,"interventions":3135},"NCT05066841","Chinese Herbal Medicine Formula Combined With Inhaled Corticosteroids for the Treatment of Mild to Persistent Asthma in Children",[89],"2023-09-30","2021-09-25",[3134],"Childhood Asthma",[3113,3136],"10% CM",{"intervention":3136,"totalTrials":93,"cells":3138},{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3140,"activeCount":97},[],{"trials":3142,"activeCount":97},[],{"trials":3144,"activeCount":97},[],{"trials":3146,"activeCount":97},[],{"trials":3148,"activeCount":97},[],{"trials":3150,"activeCount":97},[3151],{"nctId":3128,"briefTitle":3129,"status":796,"phases":3152,"primaryCompletion":2494,"completion":3131,"start":3132,"enrollment":1542,"conditions":3153,"interventions":3154},[89],[3134],[3113,3136]]